These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 29941458)

  • 1. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
    Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia.
    Pan L; Chen Y; Weng K; Guo B; Zhuang S; Huang S; Lian Z; Wang X; Li N; Zheng Y
    BMC Cancer; 2024 Aug; 24(1):1070. PubMed ID: 39210321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
    Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
    Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
    Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
    Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
    Burns MA; Place AE; Stevenson KE; Gutiérrez A; Forrest S; Pikman Y; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Gennarini LM; Kahn JM; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28719. PubMed ID: 33026184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of IKZF1 gene copy number abnormalities in BCR/ABL-negative B-lineage acute lymphoblastic leukemia in children].
    Zou Y; Liu XM; Zhang L; Chen YM; Guo Y; Chen XJ; Yang WY; Wang SC; Ruan M; Liu TF; Zhang JY; Liu F; Qi BQ; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov; 17(11):1154-9. PubMed ID: 26575870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
    Clappier E; Grardel N; Bakkus M; Rapion J; De Moerloose B; Kastner P; Caye A; Vivent J; Costa V; Ferster A; Lutz P; Mazingue F; Millot F; Plantaz D; Plat G; Plouvier E; Poirée M; Sirvent N; Uyttebroeck A; Yakouben K; Girard S; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
    Leukemia; 2015 Nov; 29(11):2154-61. PubMed ID: 26050650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
    Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
    Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IKZF1
    Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
    J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.
    Asai D; Imamura T; Suenobu S; Saito A; Hasegawa D; Deguchi T; Hashii Y; Matsumoto K; Kawasaki H; Hori H; Iguchi A; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Oda M;
    Cancer Med; 2013 Jun; 2(3):412-9. PubMed ID: 23930217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of IKZF1 deletions and IKZF1
    Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
    Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
    Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
    Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
    Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
    Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.
    Gupta SK; Bakhshi S; Gupta R; Sharma P; Pushpam D; Sahoo RK; Kamal VK
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e666-e673. PubMed ID: 33906825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
    Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
    Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
    BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
    Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.